Atteck Bio Announces Completion of Series A Financing to Advance ATTEC-Based Degrader Drug Candidate ATCN1001 for Parkinson’s Disease
Aiteke Biotechnology Co., Ltd.The company (hereinafter referred to as “Artec”) recently announced the completion of its Series A financing round, led byShanghai Biomedical Innovation and Transformation Fund under SIIC CapitalCo-investment with Sanfu Fund. The funds raised in this round will be used to improve and optimize novel molecular glue drugs, and to advance the preclinical research of candidate molecules for Parkinson's disease.
A-Tec is the world’s first next-generation platform for developing novel protein-degrading therapeutics. Its core technology stems from Autophagy-Targeting Chimera (ATTEC), a protein autophagy degradation technology published by Fudan University in the main journal of Nature in 2019. A-Tec has established collaborations with global pharmaceutical giants, and its pipeline of neurodegenerative disease therapies developed on the ATTEC platform has gained international recognition. Prior to this financing round, the company had received investments from prominent institutions, including Sequoia China and Shulan Junjie Capital, an affiliate of Shulan Medical Group.
Ataike’s lead candidate, ATCN1001, is a molecular glue drug targeting Parkinson’s disease. Compared with other clinical-stage investigational drugs, it offers advantages such as low molecular weight, favorable druggability, low cost, and strong blood–brain barrier penetration. Leveraging the ATTEC technology platform, this novel molecular glue effectively induces autophagic degradation of pathogenic proteins within brain neurons, addressing key limitations such as insufficient efficacy of existing investigational and marketed therapies. ATCN1001 demonstrates favorable druggability characteristics and pharmacokinetic (PK) profiles, with robust target degradation efficiency observed in in vivo studies. Ataike is actively advancing molecular optimization and preparing for its Investigational New Drug (IND) application.
Ding Yu
Founder of Aiteke
“We extend our sincere gratitude to both new and existing shareholders for their recognition and support of the ATTEC team. The core advantages of ATTEC technology lie in its unique small-molecule screening system and highly efficient degradation capability. The company has established three core departments—high-throughput screening, drug design, and pharmacological research—building a comprehensive technical platform that spans the entire process from target validation to drug optimization. The funding from this round will accelerate the development of the company’s current pipeline, continuously expand novel therapies for “undruggable” targets, and establish ATTEC as a globally leading enterprise in protein degradation drug R&D.”
Lu Boxun
Chief Scientist at Atek
“Over the past few years, the Atek team has advanced projects with global competitiveness to the Preclinical Candidate (PCC) selection stage, leveraging its proprietary technology platform and cohesive teamwork. This round of funding will strongly support the advancement of our Central Nervous System (CNS) pipeline into clinical trials and accelerate the development of new platform technologies. I am confident that the advantages of our proprietary technologies will continue to emerge as projects progress, enabling us to fulfill our mission of benefiting patients at an earlier date.”
Guo Qiushan
Partner, Shanghai Biopharmaceutical Fund
“The number of patients with Parkinson’s disease continues to rise alongside population aging. Current therapies primarily rely on dopamine-based mechanisms to control symptoms, but long-term use is associated with significant motor complications. Drugs under development also commonly face challenges such as insufficient efficacy and high barriers to clinical translation. Leveraging its proprietary ATTEC technology, Artek Therapeutics enables highly efficient targeted degradation of intracellular protein aggregates. Furthermore, by utilizing its self-developed high-throughput screening platform, the company has breakthroughly addressed the core bottleneck in molecular glue interaction screening. ATCN1001 demonstrates excellent in vitro and in vivo activity as well as oral bioavailability potential, positioning it as a promising breakthrough innovative therapy for Parkinson’s disease and offering a novel solution to address the unmet clinical needs of current patients.”
Li Zhengxiong
Head of the Sanfu Fund at Furong Investment
“We are honored to have completed a strategic investment in ATTEC, an original technology developed by Fudan University. As a technology transfer fund rooted in Fudan University and dedicated to serving innovation, Sanfu Fund has always been committed to its mission of “driving laboratory breakthroughs toward industrial transformation.” The ATTEC technology stems from a disruptive discovery by Fudan University’s research team. By leveraging the “autophagosome-tethering compound” mechanism, it offers novel therapeutic pathways for multiple major diseases, particularly in the degradation of abnormal intracellular proteins, with research data demonstrating excellent results. Sanfu Fund will leverage capital as a bridge to integrate Fudan University’s disciplinary ecosystem with industry resources, facilitating ATTEC’s technical validation and clinical translation, so that more patients can benefit at an earlier stage from this groundbreaking, China-originated innovation.”